{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:34:12Z","timestamp":1774402452504,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00939-y","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T07:03:01Z","timestamp":1699426981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MRD negativity: considerations for older adults with multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"939_CR1","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139:492\u2013501.","journal-title":"Blood"},{"key":"939_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jgo.2020.10.009","volume":"12","author":"HS Mian","year":"2021","unstructured":"Mian HS, Seow H, Wildes TM, Kouroukis CT, Pond GR, Sivapathasundaram B, et al. Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: a population-based study. J Geriatr Oncol. 2021;12:508\u201314.","journal-title":"J Geriatr Oncol"},{"key":"939_CR4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36:1066\u201377.","journal-title":"Leukemia"},{"key":"939_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00843-5","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study. Blood Cancer J. 2023;13:76.","journal-title":"Blood Cancer J"},{"key":"939_CR6","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1182\/blood.V126.23.4181.4181","volume":"126","author":"B Paiva","year":"2015","unstructured":"Paiva B, Cedena T, Puig N, Cordon L, Martinez-L\u00f3pez J, Ocio EM, et al. The relevance of minimal residual disease (MRD) monitoring in elderly multiple myeloma (MM) patients. Blood. 2015;126:4181.","journal-title":"Blood"},{"key":"939_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood.V128.22.245.245","volume":"128","author":"RM de Tute","year":"2016","unstructured":"de Tute RM, Rawstron AC, Cairns DA, Pawlyn C, Davies FE, Collett C, et al. Impact of minimal residual disease in transplant ineligible myeloma patients: results from the UK NCRI Myeloma XI Trial. Blood. 2016;128:245.","journal-title":"Blood"},{"key":"939_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hon.3038","volume":"40","author":"T Facon","year":"2022","unstructured":"Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022;40:1020\u20139.","journal-title":"Hematol Oncol"},{"key":"939_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133:1953\u201363.","journal-title":"Blood"},{"key":"939_CR10","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","volume":"124","author":"M-V Mateos","year":"2014","unstructured":"Mateos M-V, Oriol A, Mart\u00ednez-L\u00f3pez J, Teruel A-I, L\u00f3pez de la Gu\u00eda A, L\u00f3pez J, et al. GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood. 2014;124:1887\u201393.","journal-title":"Blood"},{"key":"939_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:1317\u201330.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00939-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00939-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00939-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T07:03:49Z","timestamp":1699427029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00939-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00939-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HM: Honoraria: BMS, Janssen, Abbvie, Pfizer, Forus, GSK, Sanofi, Amgen, Takeda. CPV: Honoraria: BMS, Janssen, Abbvie, Pfizer, Forus, GSK, Sanofi. RF: Consulting: AbbVie, Adaptive Biotechnologies, AMGEN, AZeneca, Bayer, Binding Site, BMS (Celgene), Millenium Takeda, Jansen, Juno, Kite, Merck, Pfizer, Pharmacyclics, Regeneron, Sanofi; Scientific Advisory Boards: Adaptive Biotechnologies, Caris Life Sciences, Oncotracker; Board of Directors: Antegene (for profit), AZBio (not for profit); patent for FISH in MM\u2014~$2000\/year.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}